SAN DIEGO, Oct. 02, 2024 (GLOBE NEWSWIRE) — Destiny Therapeutics, Inc. (NASDAQ: NASDAQ:), a clinical-stage biopharmaceutical firm devoted to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived mobile immunotherapies to sufferers with most cancers and autoimmune ailments, immediately introduced that on October 1, 2024 the Firm granted restricted inventory models (RSUs) representing 16,400 shares of its widespread inventory to 2 newly-hired non-executive staff. The grants had been authorized by the Compensation Committee of the Firm’s Board of Administrators and granted beneath the Firm’s Amended and Restated Inducement Fairness Plan as an inducement materials to the brand new staff getting into into employment with the Firm in accordance with Nasdaq Itemizing Rule 5635(c)(4). The RSUs will vest over 4 years, with 25% of the shares underlying every RSU award vesting on every anniversary of the grant date, topic to the worker being repeatedly employed by the Firm by every vesting date.
About Destiny Therapeutics, Inc.
Destiny Therapeutics is a clinical-stage biopharmaceutical firm devoted to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived mobile immunotherapies to sufferers with most cancers and autoimmune ailments. Utilizing its proprietary iPSC product platform, the Firm has established a management place in creating multiplexed-engineered iPSC strains and within the manufacture and medical growth of off-the-shelf, iPSC-derived cell merchandise. The Firm’s pipeline consists of iPSC-derived pure killer (NK) cell and T-cell product candidates, that are selectively designed, incorporate novel artificial controls of cell operate, and are meant to ship a number of therapeutic mechanisms to sufferers. Destiny Therapeutics is headquartered in San Diego, CA. For extra info, please go to www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com